Azvudine reduces COVID-19 risk: real-time meta-analysis of 42 studies (Version 43)

Significantly lower risk is seen for mortality, ICU admission, hospitalization, progression, and viral clearance. 32 studies from 22 independent teams in 2 countries show significant benefit.

Meta-analysis using the most serious outcome reported shows 27% [19‑33%] lower risk. Results are similar for Randomized Controlled Trials, higher quality studies, and peer-reviewed studies.

Results are very robust—in worst case exclusion sensitivity analysis 22 of 42 studies must be excluded before statistical significance is lost.

Control Azvudine

Azvudine is a nucleoside analog with potential host cell and organ toxicity. Studies to date highlight liver, reproductive, and hematologic toxicity - there is not the same volume of evidence for harm as there is with remdesivir, but there is also less data overall. Therefore, results may be less favorable with longer follow-up, and long-term morbidity could be an issue. COVID-19 studies show significantly increased risk of liver injury1,2.

No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. All data and sources to reproduce this analysis are in the appendix.

5 other meta-analyses show significant improvements with azvudine for mortality3-7, mechanical ventilation3, clinical improvement3, progression7, and viral clearance3,5,6.

5 meta-analyses show significant improvements with azvudine for mortality1-5, mechanical ventilation1, improvement1, progression5, and viral clearance1,3,4.